Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection

Lancet

Volumn 350, Issue 9081, 1997, Pages 855-859

  Gough, Andrew ^a,c   Clapperton, Mary ^b   Rolando, Nancy ^b   Foster, Alethea V M ^a   Philpott Howard, John ^b   Edmonds, Michael E ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CYTOKINE; FLUCLOXACILLIN; INSULIN; METRONIDAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SUPEROXIDE; ZYMOSAN;

ADJUVANT THERAPY; ADULT; AGED; AMPUTATION; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; BONE MARROW; CELL STIMULATION; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC FOOT; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; INSULIN TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MALE; MORBIDITY; MORTALITY; NEUTROPHIL; PRIORITY JOURNAL; SPECTROPHOTOMETRY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030870410     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)04495-4     Document Type: Article

References (31)

1. Williams DRR. The size of the problem: epidemiological and economic aspects of foot problems in diabetes. In: Boulton AJM, Connor H, Cavanagh PR, eds. The foot in diabetes, 2nd edn. New York: Wiley 1994: 15-24.
2. Bridges RM, Deitch EA. Diabetic foot infections: pathophysiology and treatment. Surg Clin North Am 1994; 74: 537-55.
3. Apelqvist J, Ragnarson-Tennvall G, Persson U, Larsson J. Diabetic foot ulcers in a multidisciplinary setting: an economic analysis of primary healing and healing with amputation. J Intern Med 1994; 235: 463-71.
4. Leibovici L, Yehezkelli Y, Porter A, Regev A, Krauze I, Harell D. Influence of diabetes mellitus and glycaemic control on the characteristics and outcome of common infections. Diabetic Med 1996; 13: 457-63.
5. Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot: soft tissue and bone infection. Infect Dis Clin North Am 1990; 4: 409-32.
6. Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 1980; 93: 480-89.
7. Mowat AG, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 1971; 284: 621-27.
8. Davidson NJ, Sowden JM, Fletcher J. Defective phagocytosis in insulin controlled diabetics: evidence for a reaction between glucose and opsonising proteins. J Clin Pathol 1984; 37: 783-86.
9. Sato N, Shimizu H, Suwa K, Shimomura Y, Mori M, Kobayashi I. Myeloperoxidase activity and generation of active oxygen species in leukocytes from poorly controlled diabetic patients. Diabetes Care 1992; 15: 1050-52.
10. Marphoffer W, Stein M, Schleinkofer L, Frederlin K. Evidence of ex vivo and in vitro impaired neutrophil oxidative burst and phagocytic capacity in type 1 diabetes mellitus. Diabetes Res Clin Pract 1993; 19: 183-88.
11. Marphoffer W, Stein M, Maeser E, Frederlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992; 15: 256-60.
12. Cebon J, Layton JE, Maher D, Morstyn G. Endogenous haemopoietic growth factors in neutropenia and infection. Br J Haematol 1994; 86: 265-74.
13. Selig C, Nothdurft W. Cytokines and progenitor cells of granulocytopoiesis in peripheral blood of patients with bacterial infections. Infect Immun 1995; 63: 104-09.
14. Dale DC, Liles WC, Summer WR, Nelson S. Granulocyte colony-stimulating factor (G-CSF): role and relationships in infectious diseases. J Infect Dis 1995; 172: 1061-75.
15. Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective neutrophils. J Infect Dis 1991; 163: 579-83.
16. Nelson S. Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the non-neutropenic host: an overview. Clin Infect Dis 1994; 18 (suppl 2): S197-204.
17. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Current concepts: assessment and management of foot disease in patients with diabetes. N Engl J Med 1994; 331: 854-60.
18. Second European consensus document on chronic critical leg ischaemia. Circulation 1991; 84 (suppl IV): 1-26.
19. Jacobs MJHM, Ubbink D T, Kitslaar PJEHM, et al. Assessment of the micro circulation provides additional information in critical limb ischaemia. Eur J Vasc Surg 1992; 6: 135-41.
20. Sanders LJ, Murray-Leisure K. Infections of the diabetic foot. In: Abramson C, McCarthy TW, eds. Infectious diseases of the lower extremity. Baltimore: Williams and Wilkins, 1991; 193-211.
21. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers: a clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995; 273: 721-23.
22. Pick E, Mizel D. Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader. J Immunol Methods 1981; 46: 211-26.
23. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam vs imipenem/cilastatin in treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994; 18: 683-93.
24. Eneroth M. Clinical characteristics and outcome in diabetic patients with deep foot infections. MD thesis: Lund University, Sweden: 1997.
25. West NJ. Systemic antimicrobial treatment of foot infections in diabetic patients. Am J Health Syst Pharm 1995; 52: 1199-1207.
26. Sato N, Kashima K, Tanaka Y, Shimizu H, Mori M. Effect of granulocyte-colony stimulating factor on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients. Diabetes 1997; 46: 133-137.
27. Boland OM, Blackwell CC, Clarke BF, Ewing DJ. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus. Diabetes 1993; 42: 336-40.
28. Nielson CP, Hindson DA. Inhibition of polymorphonuclear leukocyte respiratory burst by elevated glucose concentrations in vitro. Diabetes 1989; 38: 1031-35.
29. Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84: 2923-29.
30. Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF): a review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991; 42: 300-30.
31. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA. Leucocytes and the risk of ischemic disease. JAMA 1987; 257: 2316-24.